Helicobacter pylori (H. pylori) infection is a general condition that is usually lifelong, with a prevalence reaching approximately 50% worldwide; in China, the prevalence has recently reached 44%. In December 2021, th.e U.S. Department of Health and Human Services listed chronic H. pylori as a clear carcinogen in the 15th report on carcinogens. It has also been proven to be closely related to multiple gastrointestinal (GI) diseases such as gastric adenocarcinoma, peptic ulcer (gastric and duodenal ulcer), chronic gastritis, and mucosa-associated lymphoid tissue (MALT) lymphoma. Successful H. pylori eradication would not only benefit individuals by improving histologic gastritis, preventing gastric carcinogenesis, and reducing the risk of serious complications but also block transmission and alleviate future medical expenses. However, H. pylori eradication rates have been decreasing in recent years, while the antibiotic resistance rate continues to increase.

Hence vonoprazan a novel potassium channel blocker, may be effective as a component of H. pylori eradication therapy. Vonoprazan therapy is approved for H pylori eradication and is currently being used in practice. We at our centre prescribe both the regimens. Patients will be prescribed treatment for 14 days. Confirmation of H. Pylori eradication will be done by stool H pylori antigen test or urea breadth test at 4 weeks at the end of h pylori treatment. Data of the patients taking quadruple therapy and vonoprazan therapy will be collected. Then H.Pylori eradication rate of  both the regimens will be calculated and then will be compared